News

MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients

— Orally administered MP1032 with very favorable safety and tolerability profile

— Compound equally effective as Remdesivir or Nirmatrelvir/Ritonavir as monotherapy

— Oral administration and suitability for early intervention address high unmet medical need

MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, today announced topline data of its CT05 Phase IIa double-blind placebo-controlled study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients.

Read more…

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team

– Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise

Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Company´s management team as Head of Research and Discovery.

Dr. Burbidge is an experienced drug hunter with an in-depth expertise in both small molecule and biological drug discovery and development. He is currently Director of Discovery and Preclinical Projects at 3D Consultants, Cambridge (UK), an advisory company focusing on drug discovery and development. From 2009 to 2018, he held positions of increasing responsibility at Proximagen Ltd, Cambridge (UK), most recently as Head of Discovery and Preclinical Projects. Read more…

Allero Therapeutics Receives EIC Horizon Grant to Advance Treatment of Celiac Disease

– Specific OroMucosal ImmunoTherapy (SOMIT) for celiac disease patients supported with EUR 2.5mn funding

Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company has received a EUR 2.5 million EIC Horizon Grant provided by the European Commission to advance novel treatments for celiac disease patients. The program is based on Allero´s proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology for the treatment of antigen-driven immune disorders.

Read more…

HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer

– Significant expansion of allergy research expertise

HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced that Joana Vitte, MD, PhD, Habil. will be joining HpVac as Chief Scientific Officer.

Joana Vitte is an experienced scientist with a strong track record in allergy diagnostics and clinical research. She brings significant knowledge in human immunology, flow cytometry, and allergy testing. Among others, her work focuses on the interplay of allergic and anti-infectious immune responses. Joana Vitte has a joint position as Associate Professor of Immunology at Aix-Marseille University and the University Hospital of Marseille and is also Associate Researcher at the Institut d’Épidémiologie et de Santé Publique (IDESP) of the University of Montpellier. She is also Vice President for science and education at the French Society of Allergology.

Read more…

1 2 174